Sirtuin inhibitors as anticancer agents

References

• 1 Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289(5487), 2126–2128 (2000).
  Medline CASGoogle Scholar
• 2 Imai SI, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403(6771), 795–800 (2000).
  Medline CASGoogle Scholar
• 3 Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5(1), 253–295 (2010).
  Medline CASGoogle Scholar
• 4 Morris BJ. Seven sirtuins for seven deadly diseases of aging. Free Radic. Biol. Med. 56(0), 133–171 (2013).
  Medline CASGoogle Scholar
• 5 Roth M, Chen WY. Sorting out functions of sirtuins in cancer. Oncogene doi:10.1038/onc.2013.120 (2013) (Epub ahead of print).
  Google Scholar
• 6 Lin Z, Fang D. The roles of SIRT1 in cancer. Genes Cancer 4(3–4), 97–104 (2013).
  Medline CASGoogle Scholar
• 7 Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann. NY Acad. Sci. 1271, 10–19 (2012).
  Medline CASGoogle Scholar
• 8 Firestein R, Blander G, Michan S et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 3(4), e2020 (2008).
  MedlineGoogle Scholar
• 9 Herranz D, Munoz-Martin M, Canamero M et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 1, 3 (2010).
  MedlineGoogle Scholar
• 10 Wang RH, Sengupta K, Li C et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14(4), 312–323 (2008).
  Medline CASGoogle Scholar
• 11 Yeung F, Hoberg JE, Ramsey CS et al. Modulation of NF-êB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23, 2369–2380 (2004).
  Medline CASGoogle Scholar
• 12 Lim J-H, Lee Y-M, Chun Y-S, Chen J, Kim J-E, Park J-W. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α. Mol. Cell 38(6), 864–878 (2010).
  Medline CASGoogle Scholar
• 13 Wang R-H, Zheng Y, Kim H-S et al. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol. Cell 32(1), 11–20 (2008).
  MedlineGoogle Scholar
• 14 Herranz D, Maraver A, Canamero M et al. SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene 32(34), 4052–4056 (2013).
  Medline CASGoogle Scholar
• 15 Yuan H, Wang Z, Li L et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119(8), 1904–1914 (2012).
  Medline CASGoogle Scholar
• 16 Leko V, Park GJ, Lao U, Simon JA, Bedalov A. Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+/min) mouse model. PLoS ONE 8(6), e66283 (2013).
  Medline CASGoogle Scholar
• 17 Chen L. Medicinal chemistry of sirtuin inhibitors. Curr. Med. Chem. 18(13), 1936–1946 (2011).
  Medline CASGoogle Scholar
• 18 Wang Z, Yuan H, Roth M, Stark JM, Bhatia R, Chen WY. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene 32(5), 589–598 (2013).
  Medline CASGoogle Scholar
• 19 Luo J, Nikolaev AY, Imai SI et al. Negative control of p53 by Sir2a promotes cell survival under stress. Cell 107(2), 137–148 (2001).
  Medline CASGoogle Scholar
• 20 Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 24(5), 1021–1032 (2005).
  Medline CASGoogle Scholar
• 21 Wang F, Chan CH, Chen K, Guan X, Lin HK, Tong Q. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 31(12), 1546–1557 (2012).
  Medline CASGoogle Scholar
• 22 Daitoku H, Hatta M, Matsuzaki H et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc. Natl Acad. Sci. USA 101(27), 10042–10047 (2004).
  Medline CASGoogle Scholar
• 23 Choi HK, Cho KB, Phuong NT et al. SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells. Mol. Pharm. 10(7), 2517–2527 (2013).
  Medline CASGoogle Scholar
• 24 Menssen A, Hydbring P, Kapelle K et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc. Natl Acad. Sci. USA 109(4), E187–E196 (2012).
  Medline CASGoogle Scholar
• 25 Marshall GM, Liu PY, Gherardi S et al. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet. 7(6), e1002135 (2011).
  Medline CASGoogle Scholar
• 26 Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc–SIRT1 feedback loop regulates cell growth and transformation. J. Cell Biol. 185(2), 203–211 (2009).
  Medline CASGoogle Scholar
• 27 Holloway KR, Calhoun TN, Saxena M et al. SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc. Natl Acad. Sci. USA 107(20), 9216–9221 (2010).
  Medline CASGoogle Scholar
• 28 Saxena M, Dykes SS, Malyarchuk S, Wang AE, Cardelli JA, Pruitt K. The sirtuins promote Dishevelled-1 scaffolding of TIAM1, Rac activation and cell migration. Oncogene doi:10.1038/onc.2013.549 (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 29 Holloway KR, Barbieri A, Malyarchuk S et al. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol. Endocrinol. 27(3), 480–490 (2013).
  Medline CASGoogle Scholar
• 30 O'Hagan HM, Wang W, Sen S et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 20(5), 606–619 (2011).
  MedlineGoogle Scholar
• 31 Bosch-Presegué L, Raurell-Vila H, Marazuela-Duque A et al. Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection. Mol. Cell 42(2), 210–223 (2011).
  Medline CASGoogle Scholar
• 32 Murayama A, Ohmori K, Fujimura A et al. Epigenetic control of rDNA loci in response to intracellular energy status. Cell 133(4), 627–639 (2008).
  Medline CASGoogle Scholar
• 33 Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123(3), 437–448 (2005).
  Medline CASGoogle Scholar
• 34 Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306(5704), 2105–2108 (2004).
  Medline CASGoogle Scholar
• 35 Gallardo E, Navarro A, Vinolas N et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30(11), 1903–1909 (2009).
  Medline CASGoogle Scholar
• 36 Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl Acad. Sci. USA 105(36), 13421–13426 (2008).
  Medline CASGoogle Scholar
• 37 Kim H-S, Vassilopoulos A, Wang R-H et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20(4), 487–499 (2011).
  Medline CASGoogle Scholar
• 38 Serrano L, Martinez-Redondo P, Marazuela-Duque A et al. The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev. 27(6), 639–653 (2013).
  Medline CASGoogle Scholar
• 39 Lin R, Tao R, Gao X et al. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol. Cell 51(4), 506–518 (2013).
  Medline CASGoogle Scholar
• 40 Heltweg B, Gatbonton T, Schuler AD et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66(8), 4368–4377 (2006).
  Medline CASGoogle Scholar
• 41 Li Y, Matsumori H, Nakayama Y et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells 16(1), 34–45 (2011).
  Medline CASGoogle Scholar
• 42 Liu G, Su L, Hao X et al. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J. Cell. Mol. Med. 16(7), 1618–1628 (2012).
  Medline CASGoogle Scholar
• 43 Liu PY, Xu N, Malyukova A et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 20(3), 503–514 (2013).
  Medline CASGoogle Scholar
• 44 Sunami Y, Araki M, Hironaka Y et al. Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells. PLoS ONE 8(2), e57633 (2013).
  Medline CASGoogle Scholar
• 45 Chen J, Chan AW, To KF et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3beta/beta-catenin signaling. Hepatology 57(6), 2287–2298 (2013).
  Medline CASGoogle Scholar
• 46 He X, Nie H, Hong Y, Sheng C, Xia W, Ying W. SIRT2 activity is required for the survival of C6 glioma cells. Biochem. Biophys. Res. Comm. 417(1), 468–472 (2012).
  Medline CASGoogle Scholar
• 47 McCarthy AR, Sachweh MC, Higgins M et al. Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner. Mol. Cancer. Ther. 12(4), 352–360 (2013).
  Medline CASGoogle Scholar
• 48 Zhang Y, Au Q, Zhang M, Barber JR, Ng SC, Zhang B. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem. Biophys. Res. Commun. 386(4), 729–733 (2009).
  Medline CASGoogle Scholar
• 49 Yang MH, Laurent G, Bause AS et al. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol. Cancer Res. 11(9), 1072–1077 (2013).
  Medline CASGoogle Scholar
• 50 Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. 6(2), 105–114 (2007).
  Medline CASGoogle Scholar
• 51 Zhao Y, Yang J, Liao W et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat. Cell Biol. 12(7), 665–675 (2010).
  Medline CASGoogle Scholar
• 52 Ramakrishnan G, Davaakhuu G, Kaplun L et al. Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin. J. Biol. Chem. 289(9), 6054–6066 (2014).
  Medline CASGoogle Scholar
• 53 Zhao D, Zou S-W, Liu Y et al. Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell 23(4), 464–476 (2013).
  Medline CASGoogle Scholar
• 54 Soung YH, Pruitt K, Chung J. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells. Sci. Rep. 4, 3846 (2014).
  MedlineGoogle Scholar
• 55 Kim HS, Patel K, Muldoon-Jacobs K et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17(1), 41–52 (2010).
  Medline CASGoogle Scholar
• 56 Finley LW, Carracedo A, Lee J et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 19(3), 416–428 (2011).
  Medline CASGoogle Scholar
• 57 Bell EL, Emerling BM, Ricoult SJ, Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene 30(26), 2986–2996 (2011).
  Medline CASGoogle Scholar
• 58 Shulga N, Wilson-Smith R, Pastorino JG. Sirtuin-3 deacetylation of cyclophilin D induces dissociation of hexokinase II from the mitochondria. J. Cell Sci. 123(Pt 6), 894–902 (2010).
  Medline CASGoogle Scholar
• 59 Hafner AV, Dai J, Gomes AP et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY), 2(12), 914–923 (2010).
  Medline CASGoogle Scholar
• 60 Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 119(9), 2758–2771 (2009).
  Medline CASGoogle Scholar
• 61 Jacobs KM, Pennington JD, Bisht KS et al. SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression. Int. J. Biol. Sci. 4(5), 291–299 (2008).
  Medline CASGoogle Scholar
• 62 Tseng AH, Shieh SS, Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic. Biol. Med. 63, 222–234 (2013).
  Medline CASGoogle Scholar
• 63 Inuzuka H, Gao D, Finley LW et al. Acetylation-dependent regulation of Skp2 function. Cell 150(1), 179–193 (2012).
  Medline CASGoogle Scholar
• 64 Iwahara T, Bonasio R, Narendra V, Reinberg D. SIRT3 functions in the nucleus in the control of stress-related gene expression. Mol. Cell. Biol. 32(24), 5022–5034 (2012).
  Medline CASGoogle Scholar
• 65 Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol. Cell Biol. 28(20), 6384–6401 (2008).
  Medline CASGoogle Scholar
• 66 Haigis MC, Mostoslavsky R, Haigis KM et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126(5), 941–954 (2006).
  Medline CASGoogle Scholar
• 67 Csibi A, Fendt SM, Li C et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153(4), 840–854 (2013).
  Medline CASGoogle Scholar
• 68 Jeong SM, Xiao C, Finley LW et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 23(4), 450–463 (2013).
  Medline CASGoogle Scholar
• 69 Yu J, Sadhukhan S, Noriega LG et al. Metabolic characterization of a Sirt5 deficient mouse model. Sci. Rep. 3, 2806 (2013).
  MedlineGoogle Scholar
• 70 Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137(3), 560–570 (2009).
  Medline CASGoogle Scholar
• 71 Du J, Zhou Y, Su X et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334(6057), 806–809 (2011).
  Medline CASGoogle Scholar
• 72 Peng C, Lu Z, Xie Z et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol. Cell. Proteomics 10(12), M111.012658 (2011).
  Google Scholar
• 73 Park J, Chen Y, Tishkoff DX et al. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol. Cell 50(6), 919–930 (2013).
  Medline CASGoogle Scholar
• 74 Michishita E, McCord RA, Berber E et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452(7186), 492–496 (2008).
  Medline CASGoogle Scholar
• 75 Sebastian C, Zwaans BM, Silberman DM et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151(6), 1185–1199 (2012).
  Medline CASGoogle Scholar
• 76 Jiang H, Khan S, Wang Y et al. SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine. Nature 496(7443), 110–113 (2013).
  Medline CASGoogle Scholar
• 77 Gil R, Barth S, Kanfi Y, Cohen HY. SIRT6 exhibits nucleosome-dependent deacetylase activity. Nucleic Acids Res. 41(18), 8537–8545 (2013).
  Medline CASGoogle Scholar
• 78 Feldman JL, Baeza J, Denu JM. Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. J. Biol. Chem. 288(43), 31350–31356 (2013).
  Medline CASGoogle Scholar
• 79 Mostoslavsky R, Chua KF, Lombard DB et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124(2), 315–329 (2006).
  Medline CASGoogle Scholar
• 80 Chen S, Seiler J, Santiago-Reichelt M, Felbel K, Grummt I, Voit R. Repression of RNA polymerase I upon stress is caused by inhibition of RNA-dependent deacetylation of PAF53 by SIRT7. Mol. Cell 52(3), 303–313 (2013).
  Medline CASGoogle Scholar
• 81 Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16(10), 4623–4635 (2005).
  Medline CASGoogle Scholar
• 82 Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 20(9), 1075–1080 (2006).
  Medline CASGoogle Scholar
• 83 Tsai YC, Greco TM, Cristea IM. SIRT7 plays a role in ribosome biogenesis and protein synthesis. Mol. Cell. Proteomics 13(1), 73–83 (2013).
  MedlineGoogle Scholar
• 84 Barber MF, Michishita-Kioi E, Xi Y et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 487(7405), 114–118 (2012).
  Medline CASGoogle Scholar
• 85 Shin J, He M, Liu Y et al. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. 5(3), 654–665 (2013).
  Medline CASGoogle Scholar
• 86 Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci. 35, 146–154 (2014).
  Medline CASGoogle Scholar
• 87 Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J. Biol. Chem., 278(51), 50985–50998 (2003).
  Medline CASGoogle Scholar
• 88 Smith BC, Denu JM. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. Biochemistry 46(50), 14478–14486 (2007).
  Medline CASGoogle Scholar
• 89 Hawse WF, Hoff KG, Fatkins DG et al. Structural insights into intermediate steps in the Sir2 deacetylation reaction. Structure 16(9), 1368–1377 (2008).
  Medline CASGoogle Scholar
• 90 Hu J, He B, Bhargava S, Lin H. A fluorogenic assay for screening Sirt6 modulators. Org. Biomol. Chem. 11(32), 5213–5216 (2013).
  Medline CASGoogle Scholar
• 91 Tervo AJ, Kyrylenko S, Niskanen P et al. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J. Med. Chem. 47(25), 6292–6298 (2004).
  Medline CASGoogle Scholar
• 92 Audrito V, Vaisitti T, Rossi D et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 71(13), 4473–4483 (2011).
  Medline CASGoogle Scholar
• 93 Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J. Biol. Chem. 284(6), 3823–3832 (2009).
  Medline CASGoogle Scholar
• 94 Suzuki T, Khan MN, Sawada H et al. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. J. Med. Chem. 55(12), 5760–5773 (2012).
  Medline CASGoogle Scholar
• 95 Taylor DM, Balabadra U, Xiang Z et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol. 6(6), 540–546 (2011).
  Medline CASGoogle Scholar
• 96 Mai A, Valente S, Meade S et al. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J. Med. Chem. 52(17), 5496–5504 (2009).
  Medline CASGoogle Scholar
• 97 Alvala M, Bhatnagar S, Ravi A et al. Novel acridinedione derivatives: design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies. Bioorg. Med. Chem. Lett. 22(9), 3256–3260 (2012).
  Medline CASGoogle Scholar
• 98 Alhazzazi TY, Kamarajan P, Joo N et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 117(8), 1670–1678 (2011).
  Medline CASGoogle Scholar
• 99 Smith BC, Denu JM. Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases. J. Biol. Chem. 282(51), 37256–37265 (2007).
  Medline CASGoogle Scholar
• 100 Fatkins DG, Monnot AD, Zheng W. Nepsilon-thioacetyl-lysine: a multi-facet functional probe for enzymatic protein lysine Nepsilon-deacetylation. Bioorg. Med. Chem. Lett. 16(14), 3651–3656 (2006).
  Medline CASGoogle Scholar
• 101 Kiviranta PH, Suuronen T, Wallen EA et al. N(epsilon)-thioacetyl-lysine-containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors. J. Med. Chem. 52(7), 2153–2156 (2009).
  Medline CASGoogle Scholar
• 102 Jamonnak N, Fatkins DG, Wei L, Zheng W. N(epsilon)-methanesulfonyl-lysine as a non-hydrolyzable functional surrogate for N(epsilon)-acetyl-lysine. Org. Biomol. Chem. 5(6), 892–896 (2007).
  Medline CASGoogle Scholar
• 103 Huhtiniemi T, Suuronen T, Lahtela-Kakkonen M et al. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2. Bioorg. Med. Chem. 18(15), 5616–5625 (2010).
  Medline CASGoogle Scholar
• 104 Chakrabarty SP, Ramapanicker R, Mishra R, Chandrasekaran S, Balaram H. Development and characterization of lysine based tripeptide analogues as inhibitors of Sir2 activity. Bioorg. Med. Chem. 17(23), 8060–8072 (2009).
  Medline CASGoogle Scholar
• 105 Hirsch BM, Hao Y, Li X, Wesdemiotis C, Wang Z, Zheng W. A mechanism-based potent sirtuin inhibitor containing Nepsilon-thiocarbamoyl-lysine (TuAcK). Bioorg. Med. Chem. Lett. 21(16), 4753–4757 (2011).
  Medline CASGoogle Scholar
• 106 Jamonnak N, Hirsch BM, Pang Y, Zheng W. Substrate specificity of SIRT1-catalyzed lysine Nepsilon-deacetylation reaction probed with the side chain modified Nepsilon-acetyl-lysine analogs. Bioorg. Chem. 38(1), 17–25 (2010).
  Medline CASGoogle Scholar
• 107 Suzuki T, Asaba T, Imai E, Tsumoto H, Nakagawa H, Miyata N. Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine. Bioorg. Med. Chem. Lett. 19(19), 5670–5672 (2009).
  Medline CASGoogle Scholar
• 108 Huhtiniemi T, Salo HS, Suuronen T et al. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2. J. Med. Chem. 54(19), 6456–6468 (2011).
  Medline CASGoogle Scholar
• 109 Mellini P, Kokkola T, Suuronen T et al. Screen of pseudopeptidic inhibitors of human sirtuins 1–3: two lead compounds with antiproliferative effects in cancer cells. J. Med. Chem. 56(17), 6681–6695 (2013).
  Medline CASGoogle Scholar
• 110 Morimoto J, Hayashi Y, Suga H. Discovery of macrocyclic peptides armed with a mechanism-based warhead: isoform-selective inhibition of human deacetylase SIRT2. Angew. Chem. Int. Ed. Engl. 51(14), 3423–3427 (2012).
  Medline CASGoogle Scholar
• 111 Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276(42), 38837–38843 (2001).
  Medline CASGoogle Scholar
• 112 Ota H, Tokunaga E, Chang K et al. Sirt1 inhibitor, sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25(2), 176–185 (2006).
  Medline CASGoogle Scholar
• 113 Peck B, Chen CY, Ho KK et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther. 9(4), 844–855 (2010).
  Medline CASGoogle Scholar
• 114 Kojima K, Ohhashi R, Fujita Y et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 373(3), 423–428 (2008).
  Medline CASGoogle Scholar
• 115 Jin KL, Park JY, Noh EJ et al. The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J. Gynecol. Oncol. 21(4), 262–268 (2010).
  Medline CASGoogle Scholar
• 116 Kalle AM, Mallika A, Badiger J, Alinakhi, Talukdar P, Sachchidanand. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem. Biophys. Res. Commun. 401(1), 13–19 (2010).
  Medline CASGoogle Scholar
• 117 Lara E, Mai A, Calvanese V et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28(6), 781–791 (2009).
  Medline CASGoogle Scholar
• 118 Rotili D, Tarantino D, Nebbioso A et al. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J. Med. Chem. 55(24), 10937–10947 (2012).
  Medline CASGoogle Scholar
• 119 Pasco MY, Rotili D, Altucci L et al. Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues. J. Med. Chem. 53(3), 1407–1411 (2010).
  Medline CASGoogle Scholar
• 120 Medda F, Russell RJ, Higgins M et al. Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J. Med. Chem. 52(9), 2673–2682 (2009).
  Medline CASGoogle Scholar
• 121 Uciechowska U, Schemies J, Neugebauer RC et al. Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing. ChemMedChem 3(12), 1965–1976 (2008).
  Medline CASGoogle Scholar
• 122 Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc. Natl Acad. Sci. USA 98(26), 15113–15118 (2001).
  Medline CASGoogle Scholar
• 123 Pagans S, Pedal A, North BJ et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 3(2), e41 (2005).
  MedlineGoogle Scholar
• 124 Neugebauer RC, Uchiechowska U, Meier R et al. Structure–activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J. Med. Chem. 51(5), 1203–1213 (2008).
  Medline CASGoogle Scholar
• 125 Rotili D, Tarantino D, Carafa V et al. Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells. J. Med. Chem. 55(18), 8193–8197 (2012).
  Medline CASGoogle Scholar
• 126 Rotili D, Tarantino D, Carafa V et al. Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors. ChemMedChem 5(5), 674–677 (2010).
  Medline CASGoogle Scholar
• 127 Napper AD, Hixon J, McDonagh T et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48(25), 8045–8054 (2005).
  Medline CASGoogle Scholar
• 128 Solomon JM, Pasupuleti R, Xu L et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 26(1), 28–38 (2006).
  Medline CASGoogle Scholar
• 129 Stunkel W, Peh BK, Tan YC et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol. J. 2(11), 1360–1368 (2007).
  Medline CASGoogle Scholar
• 130 Zhang Q, Zeng SX, Zhang Y et al. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol. Med. 4(4), 298–312 (2012).
  Medline CASGoogle Scholar
• 131 Davis PD, Hill CH, Keech E et al. Potent selective inhibitors of protein kinase C. FEBS Lett. 259(1), 61–63 (1989).
  Medline CASGoogle Scholar
• 132 Trapp J, Jochum A, Meier R et al. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem. 49(25), 7307–7316 (2006).
  Medline CASGoogle Scholar
• 133 Huber K, Schemies J, Uciechowska U et al. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins). J. Med. Chem. 53(3), 1383–1386 (2010).
  Medline CASGoogle Scholar
• 134 Suenkel B, Fischer F, Steegborn C. Inhibition of the human deacylase sirtuin 5 by the indole GW5074. Bioorg. Med. Chem. Lett. 23(1), 143–146 (2013).
  Medline CASGoogle Scholar
• 135 Cea M, Soncini D, Fruscione F et al. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS ONE 6(7), e22739 (2011).
  Medline CASGoogle Scholar
• 136 Schuetz A, Min J, Antoshenko T et al. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 15(3), 377–389 (2007).
  Medline CASGoogle Scholar
• 137 Trapp J, Meier R, Hongwiset D, Kassack MU, Sippl W, Jung M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem 2(10), 1419–1431 (2007).
  Medline CASGoogle Scholar
• 138 Lain S, Hollick JJ, Campbell J et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13(5), 454–463 (2008).
  Medline CASGoogle Scholar
• 139 McCarthy AR, Pirrie L, Hollick JJ et al. Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorg. Med. Chem. 20(5), 1779–1793 (2012).
  Medline CASGoogle Scholar
• 140 Outeiro TF, Kontopoulos E, Altmann SM et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837), 516–519 (2007).
  Medline CASGoogle Scholar
• 141 Gey C, Kyrylenko S, Hennig L et al. Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2. Angew. Chem. Int. Ed. Engl. 46(27), 5219–5222 (2007).
  Medline CASGoogle Scholar
• 142 Manjulatha K, Srinivas S, Mulakayala N et al. Ethylenediamine diacetate (EDDA) mediated synthesis of aurones under ultrasound: their evaluation as inhibitors of SIRT1. Bioorg. Med. Chem. Lett. 22(19), 6160–6165 (2012).
  Medline CASGoogle Scholar
• 143 Garske AL, Smith BC, Denu JM. Linking SIRT2 to Parkinson's disease. ACS Chem. Biol. 2(8), 529–532 (2007).
  Medline CASGoogle Scholar
• 144 Gutierrez M, Andrianasolo EH, Shin WK et al. Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula. J. Org. Chem. 74(15), 5267–5275 (2009).
  Medline CASGoogle Scholar
• 145 Friden-Saxin M, Seifert T, Landergren MR et al. Synthesis and evaluation of substituted chroman-4-one and chromone derivatives as sirtuin 2-selective inhibitors. J. Med. Chem. 55(16), 7104–7113 (2012).
  Medline CASGoogle Scholar
• 146 Disch JS, Evindar G, Chiu CH et al. Discovery of Thieno[3,2-d]pyrimidine-6-carboxamides as Potent Inhibitors of SIRT1, SIRT2, and SIRT3. J. Med. Chem. 56(9), 3666–3679 (2013).
  Medline CASGoogle Scholar
• 147 Knight ZA, Shokat KM. Chemical genetics: where genetics and pharmacology meet. Cell 128(3), 425–430 (2007).
  Medline CASGoogle Scholar
• 148 Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotech. 25(1), 84–90 (2007).
  Medline CASGoogle Scholar
• 149 Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc. Natl Acad. Sci. USA 101(50), 17456–17461 (2004).
  Medline CASGoogle Scholar
• 150 Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16(1), 127–136 (2006).
  Medline CASGoogle Scholar